[1]中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)非小细胞肺癌诊疗指南. 北京: 人民卫生出版社, 2022.
[2]National Comprehensive Cancer Network. (NCCN) Clinical Practice Guidelines in Oncology. Non-Small Cell Lung Cancer, Version 3. 2022.
[3]2022 ESMO: 973MO KEYNOTE-189 5-year update: First-line pembrolizumab(pembro) + pemetrexed (pem) and platinum vs placebo (pbo) + pem and platinum for metastatic nonsquamous NSCLC
[4]Brahmer JR, Lee JS, Ciuleanu TE, et al. Five-Year Survival Outcomes With Nivolumab Plus Ipilimumab Versus Chemotherapy as First-Line Treatment for Metastatic Non-Small Cell Lung Cancer in CheckMate 227 [published online ahead of print, 2022 Oct 12]. J Clin Oncol. 2022;101200JCO2201503.
[5]Zhang L, Wang Z, Fang J, et al. Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study. Lung Cancer. 2022;171:56-60.
[6]NMPA官网
[7]Yi-Long Wu, Yun Fan, JianYing Zhou, et al. Pembrolizumab vs chemotherapy in Chinese patients with PD-L1-positive NSCLC: 4-year update from KEYNOTE-042 China study. AACR 2022 CT555.
[8]IMpower110: updated OS analysis of atezolizumab vs platinum-based hemotherapy as first-line treatment in PD-L1–selected NSCLC. Presented at: 2020 World Conference on Lung Cancer Singapore. January 28-31, 2021. Abstract FP13.03.
[9]LBA57 - Sintilimab plus anlotinib versus platinum-based chemotherapy as first-line therapy in metastatic NSCLC (SUNRISE): An open label, multi-center, randomized, phase II study.2022 ESMO.
[10]Borghaei H, Gettinger S, Vokes EE, et al. Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer [published correction appears in J Clin Oncol. 2021 Apr 1;39(10):1190]. J Clin Oncol. 2021;39(7):723-733.
[11]5-Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel in Previously Treated, PD-L1–Positive Advanced NSCLC. Presented at: 2020 World Conference on Lung Cancer Singapore. January 28-31, 2021. Abstract FP13.01.
[12]LBA58-Sintilimab with or without IBI305 plus chemotherapy in patients with EGFR mutated non-squamous non-small cell lung cancer (EGFRm nsqNSCLC) who progressed on EGFR tyrosine-kinase inhibitors (TKIs) therapy: Second interim analysis of phase III ORIENT-31 study.2022 ESMO.
[13]Goldstraw P, Chansky K, Crowley J, et al. The IASLC Lung Cancer Staging Project: Proposals for Revision of the TNM Stage Groupings in the Forthcoming (Eighth) Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016;11(1):39-51.
[14]Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26(21):3552-3559.
[15]Passiglia F, Bertaglia V, Reale ML, et al. Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon. Cancer Treat Rev. 2021;101:102308.
[16]Wu YL, Tsuboi M, He J, et al. Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer. N Engl J Med. 2020;383(18):1711-1723.
[17]Zhong WZ, Wang Q, Mao WM, et al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study. Lancet Oncol. 2018;19(1):139-148.
[18]Yue D, Xu S, Wang Q, et al. Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial. Lancet Respir Med. 2018;6(11):863-873.
[19]中国抗癌协会肺癌专业委员会, 中华医学会肿瘤学分会肺癌学组, 中国胸部肿瘤研究协作组,等. Ⅰ~ⅢB期非小细胞肺癌完全切除术后辅助治疗指南(2021版)[J]. 中华医学杂志, 2021, 101(16):11.
[20]Felip E, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. Lancet 2021; 398: 1344–57—The appendix of this Article has been corrected as of Sept 23, 2021.
[21]Wakelee H, et al. IMpower 010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC). 2021 ASCO. Abstract 8500.
[22]N. Li, J. Ying, X. Tao, et al., P1.18-06 efficacy and safety of neoadjuvant PD-1blockade with sintilimab in resectable non-small cell lung Cancer, J. Thorac. Oncol. 14 (10) (2019) S627–S628.
[23] J. Bar, D. Urban, E. Ofek, et al., Neoadjuvant pembrolizumab (Pembro) for early stage non-small cell lung cancer (NSCLC): updated report of a phase i study, MK3475-223, J. Clin. Oncol. 37 (2019).
[24] D.J. Kwiatkowski, V.W. Rusch, J.E. Chaft, et al., Neoadjuvant atezolizumab in resectable non-small cell lung cancer (NSCLC): interim analysis and biomarker data from a multicenter study (LCMC3), J. Clin. Oncol. (2019) 37.
[25] Jia XH, Xu H, Geng LY, et al. Efficacy and safety of neoadjuvant immunotherapy in resectable nonsmall cell lung cancer: A meta-analysis. Lung Cancer. 2020;147:143-153.
[26]Forde PM, Spicer J, Lu S, et al. Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer. N Engl J Med. 2022;386(21):1973-1985.
[27]Gao S, Li N, Gao S, et al. Neoadjuvant PD-1 inhibitor (Sintilimab) in NSCLC. J Thorac Oncol. 2020;15(5):816-826.
[28]Sun C, Liu Y, Zhang P, et al. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial [published online ahead of print, 2022 Feb 22]. J Cancer Res Clin Oncol. 2022;10.1007/s00432-021-03896-w